• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

双胺苯吖啶的溶解度及皮肤毒性研究:碳酸氢钠作为局部溃疡解毒剂的疗效

Bisantrene solubility and skin toxicity studies: efficacy of sodium bicarbonate as a local ulceration antidote.

作者信息

Dorr R T, Peng Y M, Alberts D S

出版信息

Invest New Drugs. 1984;2(4):351-7. doi: 10.1007/BF00171585.

DOI:10.1007/BF00171585
PMID:6096286
Abstract

Bisantrene solubility and skin toxicity were studied in mice given intraperitoneal (IP) and intradermal (ID) drug respectively. Bisantrene (1 mg/ml) in 5% dextrose readily precipitated in the mouse peritoneum. The admixture of bisantrene into various lipophilic solvents did not reduce drug precipitation in vivo in the mouse or in vitro in human plasma at 37 degrees C. Drug stability studies using high performance liquid chromatography (HPLC) showed markedly reduced bisantrene stability at alkaline pH. Bisantrene skin toxicity in BALB/c mice was characterized by ulceration which persisted for up to four months after ID injection. Skin toxicity was consistently reduced by dilute sodium bicarbonate injection into the bisantrene extravasation site. Three clinical extravasation cases treated with sodium bicarbonate showed no bisantrene ulceration. Ineffective local antidotes included sodium cromolyn, N-acetylcysteine, hydrocortisone, and heat (which appeared to increase toxicity).

摘要

分别通过腹腔注射(IP)和皮内注射(ID)给药,研究了双胺苯吖啶在小鼠体内的溶解度和皮肤毒性。5%葡萄糖溶液中1mg/ml的双胺苯吖啶在小鼠腹膜内极易沉淀。双胺苯吖啶与各种亲脂性溶剂混合,在37℃时,并未减少其在小鼠体内或人血浆体外的沉淀。使用高效液相色谱法(HPLC)进行的药物稳定性研究表明,在碱性pH条件下,双胺苯吖啶的稳定性显著降低。BALB/c小鼠皮内注射双胺苯吖啶后,皮肤毒性表现为溃疡,持续长达四个月。向双胺苯吖啶外渗部位注射稀释的碳酸氢钠可持续减轻皮肤毒性。三例用碳酸氢钠治疗的临床外渗病例均未出现双胺苯吖啶溃疡。无效的局部解毒剂包括色甘酸钠、N-乙酰半胱氨酸、氢化可的松和热敷(似乎会增加毒性)。

相似文献

1
Bisantrene solubility and skin toxicity studies: efficacy of sodium bicarbonate as a local ulceration antidote.双胺苯吖啶的溶解度及皮肤毒性研究:碳酸氢钠作为局部溃疡解毒剂的疗效
Invest New Drugs. 1984;2(4):351-7. doi: 10.1007/BF00171585.
2
The limited role of corticosteroids in ameliorating experimental doxorubicin skin toxicity in the mouse.皮质类固醇在减轻小鼠实验性阿霉素皮肤毒性中的有限作用。
Cancer Chemother Pharmacol. 1980;5(1):17-20. doi: 10.1007/BF00578557.
3
Phase II evaluation of bisantrene hydrochloride in refractory malignant melanoma. A Southwest Oncology Group Study.盐酸比生群用于难治性恶性黑色素瘤的II期评估。西南肿瘤学组研究。
Invest New Drugs. 1987;5(3):289-92. doi: 10.1007/BF00175300.
4
Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study.阿霉素、比生群和米托蒽醌治疗晚期乳腺癌的随机试验:西南肿瘤学组研究
J Natl Cancer Inst. 1991 Aug 7;83(15):1077-84. doi: 10.1093/jnci/83.15.1077.
5
N-phosphoryl derivatives of bisantrene. Antitumor prodrugs with enhanced solubility and reduced potential for toxicity.双蒽环类的N-磷酰基衍生物。具有增强溶解性和降低毒性潜力的抗肿瘤前药。
J Med Chem. 1993 Jul 23;36(15):2098-101. doi: 10.1021/jm00067a007.
6
Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay.
Cancer Res. 1982 Mar;42(3):1170-5.
7
A phase I and pharmacokinetic comparison of hepatic arterial and peripheral vein infusions of bisantrene for liver cancer.比生群经肝动脉和外周静脉输注治疗肝癌的I期及药代动力学比较
Cancer Chemother Pharmacol. 1985;15(2):144-8. doi: 10.1007/BF00257525.
8
Experimental studies and phase II trial of bisantrene in advanced urothelial malignancies.比生群用于晚期尿路上皮恶性肿瘤的实验研究及II期试验。
Cancer Invest. 1985;3(2):123-7. doi: 10.3109/07357908509017495.
9
Bisantrene, an active drug in patients with advanced breast cancer.比生群,一种对晚期乳腺癌患者有效的药物。
Cancer Treat Rep. 1984 Feb;68(2):357-60.
10
Phase II trial of bisantrene in patients with intermediate and high grade diffuse non-Hodgkin's lymphomas.比生群用于中、高度弥漫性非霍奇金淋巴瘤患者的II期试验。
Invest New Drugs. 1984;2(1):75-7. doi: 10.1007/BF00173790.

引用本文的文献

1
Lack of experimental vesicant activity for the anticancer agents cisplatin, melphalan, and mitoxantrone.抗癌药物顺铂、美法仑和米托蒽醌缺乏实验性发泡活性。
Cancer Chemother Pharmacol. 1986;16(2):91-4. doi: 10.1007/BF00256155.
2
Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. II. Assay methods, adriamycin and the other antitumour antibiotics.抗肿瘤药物溶液在体外试验制备和储存过程中的稳定性。II. 检测方法、阿霉素及其他抗肿瘤抗生素
Cancer Chemother Pharmacol. 1986;17(1):1-10. doi: 10.1007/BF00299858.

本文引用的文献

1
The limited role of corticosteroids in ameliorating experimental doxorubicin skin toxicity in the mouse.皮质类固醇在减轻小鼠实验性阿霉素皮肤毒性中的有限作用。
Cancer Chemother Pharmacol. 1980;5(1):17-20. doi: 10.1007/BF00578557.
2
Experimental model of doxorubicin extravasation in the mouse.小鼠阿霉素外渗的实验模型
J Pharmacol Methods. 1980 Nov;4(3):237-50. doi: 10.1016/0160-5402(80)90016-9.
3
Activity of 9-10 anthracenedicarboxaldehyde bis[(4,5-dihydro-1 H-imidazol-2-yl)hydrazone]dihydrochloride (CL216,942) in a human tumor cloning system. Leads for phase II trials in man.
Cancer Chemother Pharmacol. 1981;6(2):141-4. doi: 10.1007/BF00262332.
4
High performance liquid chromatography of a new anticancer drug, ADCA--physicochemical properties and pharmacokinetics.一种新型抗癌药物ADCA的高效液相色谱法——理化性质与药代动力学
Life Sci. 1981 Jul 27;29(4):361-9. doi: 10.1016/0024-3205(81)90329-5.
5
Phase I clinical trial of 9,10-anthracene dicarboxaldehyde (Bisantrene) administered in a five-day schedule.
Cancer Res. 1982 Jan;42(1):354-8.
6
Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay.
Cancer Res. 1982 Mar;42(3):1170-5.
7
Disposition of bisantrene in humans and rabbits: evidence for intravascular deposition of drug as a cause of phlebitis.比生群在人和兔体内的处置:药物血管内沉积作为静脉炎病因的证据。
Cancer Res. 1983 Feb;43(2):925-9.
8
Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1 H-imidazol-2-yl)hydrazone] dihydrochloride (CL216,942).
Cancer Res. 1981 Aug;41(8):3118-21.
9
Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.抗癌药物在小鼠、大鼠、仓鼠、狗、猴和人类中毒性的定量比较。
Cancer Chemother Rep. 1966 May;50(4):219-44.